[go: up one dir, main page]

TNSN07078A1 - HUMAN GROWTH HORMONE CONJUGATES WITH GLYCEROL BRANCHED POLYETHYLENE GLYCOL, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE - Google Patents

HUMAN GROWTH HORMONE CONJUGATES WITH GLYCEROL BRANCHED POLYETHYLENE GLYCOL, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE

Info

Publication number
TNSN07078A1
TNSN07078A1 TNP2007000078A TNSN07078A TNSN07078A1 TN SN07078 A1 TNSN07078 A1 TN SN07078A1 TN P2007000078 A TNP2007000078 A TN P2007000078A TN SN07078 A TNSN07078 A TN SN07078A TN SN07078 A1 TNSN07078 A1 TN SN07078A1
Authority
TN
Tunisia
Prior art keywords
leu
ser
glu
gln
phe
Prior art date
Application number
TNP2007000078A
Other languages
French (fr)
Inventor
Rory F Finn
Ned R Siegel
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN07078(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of TNSN07078A1 publication Critical patent/TNSN07078A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne la PEGylation de l'hormone de croissance humaine (hGH) en utilisant un PEG ramifié avec du glycérol. La présente invention concerne également des procédes pour la PEGylation de la hGH. En outre, la présente invention concerne des compositions pharmaceutiques comprenant la hGH PEGgylée. Une forme de réalisation supplémentaire consiste en l'utilisation de la hGH PEGylée pour le traitement de troubles de la croissance et du développement. Phe pro Thr Ile pro Ieu ser Arg lieu Phe Asp Asn12 Ala Met Leu Arg Ala Hil Arg leu His Gln leu Ala24 Phe Asp Thr Tyr Gln Glu Phe Glu Glu Ale Tyr Ile 36 Pro LYs Glu Gln Lys Tyr Ser Phe Leu Gln Asn Pro48 Gln thr SeI' Leu Cys phe Ser Glu Ser Ile Pro Thr60 Pro ser Afin Arg Glu Glu 'l'hr Gln Gln Lys Ser Asn72 Leu Glu Leu Leu Arg Ile Ser Leu Leu Leu Ile Gln84 Ser Trp Leu Glu Pro Val Gln Ser Leu Arg Ser Val96 Phe Ala Asn Ser Leu Val Tyr Gly Ala Ser Asp Ser108 Asn val Tyr Asp Leu Leu L,ys Asp Leu Glu Glu Gly120 Ile Gln Thr Leu Met Gly Arg Leu Glu Asp Gly Ser132 Pro Arg Thr Gly Gln Ile Phe Lys Gln Thr Tyr Ser 144 Lys Phe Asp Thr Asn Ser His Asn Asp Asp Ala Leu156 Leu Lys Asn Tyr Gly Leu Leu Tyr Cye Phe Arg Lys168 ASp Met Asp Lys val Glu Thr phe Leu Arg Ile Val180 Gln Cys Arg Ser Val Glu Gly ser Cys G1y Phe 191 SEQ ID NO:1The present invention relates to the PEGylation of human growth hormone (hGH) using a branched PEG with glycerol. The present invention also relates to methods for the PEGylation of hGH. In addition, the present invention relates to pharmaceutical compositions comprising PEGylated hGH. A further embodiment is the use of PEGylated hGH for the treatment of growth and developmental disorders. Phe pro Thr Pro pro Ieu ser Arg place Phe Asp Asn12 Ala Met Leu Arg Ala Hil Arg leu His Gln leu Ala24 Phe Asp Thr Tyr Tyr Gln Glu Phe Glu Glu Ale Tire Ile 36 Pro LYs Glu Gln Lys Tyr Ser Phe Gln Gln Asn Pro48 Gln thr SeI 'Leu Cys phe Ser Glu Ser Ile Pro Thr60 Pro ser Arg Glu Glu' hr Gln Gln Lys Ser Asn72 Leu Glu Leu Leu Arg Ile Ser Leu Leu Leu Ile Gln84 Ser Trp Leu Glu Pro Val Gln Ser Leu Arg Ser Val96 Phe Ala Asn Ser Leu Val Tyr Gly Ala Ser Asp Ser108 Asn val Tyr Asp Leu Leu L, ys Asp Leu Glu Glu Gly120 Ile Gln Thr Leu Met Gly Arg Leu Glu Asp Gly Ser132 Pro Arg Thr Gly Gln Ile Phe Lys Gln Thr Tyr Ser 144 Lys Phe Asp Thr Asn Ser His Asn Asp Asp Ala Leu156 Leu Lys Asn Tyr Gly Leu Leu Tyr Cye Phe Arg Lys168 ASp Met Asp Lys val Glu Thr phe Leu Arg Ile Val180 Gln Cys Arg Ser Val Glu Gly ser Cys G1y Phe 191 SEQ ID NO: 1

TNP2007000078A 2004-08-31 2007-02-27 HUMAN GROWTH HORMONE CONJUGATES WITH GLYCEROL BRANCHED POLYETHYLENE GLYCOL, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE TNSN07078A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60594504P 2004-08-31 2004-08-31
PCT/IB2005/002939 WO2006024953A2 (en) 2004-08-31 2005-08-25 Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof

Publications (1)

Publication Number Publication Date
TNSN07078A1 true TNSN07078A1 (en) 2008-06-02

Family

ID=35708806

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000078A TNSN07078A1 (en) 2004-08-31 2007-02-27 HUMAN GROWTH HORMONE CONJUGATES WITH GLYCEROL BRANCHED POLYETHYLENE GLYCOL, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE

Country Status (24)

Country Link
EP (1) EP1789092A2 (en)
JP (1) JP2008511610A (en)
KR (1) KR20070042567A (en)
CN (1) CN101010105A (en)
AP (1) AP2007003919A0 (en)
AR (1) AR050851A1 (en)
AU (1) AU2005278903A1 (en)
BR (1) BRPI0515118A (en)
CA (1) CA2577999A1 (en)
CR (1) CR8942A (en)
EA (1) EA200700380A1 (en)
EC (1) ECSP077281A (en)
GT (1) GT200500235A (en)
IL (1) IL181085A0 (en)
MA (1) MA28908B1 (en)
MX (1) MX2007002441A (en)
NL (1) NL1029828C2 (en)
NO (1) NO20071322L (en)
PE (1) PE20060654A1 (en)
TN (1) TNSN07078A1 (en)
TW (1) TW200621291A (en)
UY (1) UY29088A1 (en)
WO (1) WO2006024953A2 (en)
ZA (1) ZA200701802B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
NZ513077A (en) 1999-01-14 2004-03-26 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
US20090117077A1 (en) * 2006-05-12 2009-05-07 Dong-A Pharm. Co., Ltd. Polyethylene glycol-interferon alpha conjugate
JP2008069073A (en) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd Lactoferrin conjugate and its manufacturing method
KR101079993B1 (en) * 2006-11-17 2011-11-04 동아제약주식회사 Polyethylene glycol-G-CSF conjugate
CL2008002399A1 (en) 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
ES2523043T3 (en) * 2008-07-23 2014-11-20 Hanmi Science Co., Ltd. A polypeptide complex comprising a non-peptidyl polymer having three functional ends
MX2011001167A (en) 2008-07-31 2011-04-12 Pharmaessentia Corp Peptide-polymer conjugates.
SG195531A1 (en) * 2008-10-10 2013-12-30 Bionic Ear Inst Biodegradable polymer - bioactive moiety conjugates
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
WO2010040187A1 (en) 2008-10-10 2010-04-15 The Bionic Ear Institute Polymer-bioactive agent conjugates
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
PL2393828T3 (en) 2009-02-03 2017-06-30 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
CN101831067A (en) * 2010-05-31 2010-09-15 王二新 Polyethylene glycol ester conjugate and application thereof in medicine preparation
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (en) * 2011-04-26 2013-05-08 厦门赛诺邦格生物科技有限公司 Chain-functionalized multi-level branched polyethylene glycol and synthesis method thereof
MX366864B (en) * 2012-02-27 2019-07-26 Amunix Operating Inc Xten conjugate compositions and methods of making same.
WO2014110867A1 (en) * 2013-01-17 2014-07-24 厦门赛诺邦格生物科技有限公司 Monofunctional branched polyethyleneglycol and bio-related substance modified by same
CN104877127B (en) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 A kind of eight arms polyethyleneglycol derivative, preparation method and its bio-related substance of modification
JP6820841B2 (en) 2014-11-06 2021-01-27 ファーマエッセンティア コーポレイション Dosing regimen for pegged interferon
HRP20220041T1 (en) 2017-12-29 2022-04-15 F. Hoffmann - La Roche Ag Process for providing pegylated protein composition
US12208142B2 (en) * 2017-12-29 2025-01-28 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition
JP7227633B2 (en) * 2017-12-29 2023-02-22 エフ． ホフマン－ラ ロシュ エージー． Methods for providing PEGylated protein compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
JP3092531B2 (en) * 1996-11-05 2000-09-25 日本油脂株式会社 Method for producing imidyl succinate-substituted polyoxyalkylene derivative
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
JP3921781B2 (en) * 1998-02-12 2007-05-30 日本油脂株式会社 Carboxyl group-containing polyoxyalkylene compound
NZ513077A (en) * 1999-01-14 2004-03-26 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
MXPA04004809A (en) * 2001-11-20 2004-08-11 Pharmacia Corp Chemically-modified human growth hormone conjugates.
AP2005003246A0 (en) * 2002-09-09 2005-03-31 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
JP4412461B2 (en) * 2002-11-20 2010-02-10 日油株式会社 Modified bio-related substance, production method thereof and intermediate
AU2003303519C1 (en) * 2002-12-31 2010-08-12 Nektar Therapeutics Polymeric reagents comprising a ketone or a related functional group
NZ541374A (en) * 2003-05-23 2008-09-26 Nektar Therapeutics Al Corp PEG derivatives having an amidocarbonate linkage

Also Published As

Publication number Publication date
MX2007002441A (en) 2007-05-04
NO20071322L (en) 2007-05-29
KR20070042567A (en) 2007-04-23
AR050851A1 (en) 2006-11-29
GT200500235A (en) 2006-03-21
ECSP077281A (en) 2007-03-29
NL1029828A1 (en) 2006-03-01
UY29088A1 (en) 2006-03-31
EA200700380A1 (en) 2007-10-26
BRPI0515118A (en) 2008-07-01
WO2006024953A3 (en) 2007-01-18
WO2006024953A2 (en) 2006-03-09
IL181085A0 (en) 2007-07-04
JP2008511610A (en) 2008-04-17
MA28908B1 (en) 2007-10-01
CN101010105A (en) 2007-08-01
CA2577999A1 (en) 2006-03-09
EP1789092A2 (en) 2007-05-30
TW200621291A (en) 2006-07-01
PE20060654A1 (en) 2006-08-12
AP2007003919A0 (en) 2007-02-28
CR8942A (en) 2007-08-16
AU2005278903A1 (en) 2006-03-09
NL1029828C2 (en) 2006-10-20
ZA200701802B (en) 2008-08-27

Similar Documents

Publication Publication Date Title
TNSN07078A1 (en) HUMAN GROWTH HORMONE CONJUGATES WITH GLYCEROL BRANCHED POLYETHYLENE GLYCOL, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE
AU2017216533B2 (en) Improved peptide pharmaceuticals
ES2397852T3 (en) CGRP peptide antagonists and conjugates
AU2012255119B2 (en) Improved peptide pharmaceuticals for insulin resistance
YU5396A (en) NEW BIOLOGICAL ACTIVE PROTEINS, THEIR PHARMACEUTICAL FORMULATIONS AND THE PROCEDURE FOR THEIR DETERMINATION
US10494402B2 (en) Peptides that stimulate subcutaneous adipogenesis
EP2922876A1 (en) Improved peptide pharmaceuticals for insulin resistance
AU2015289642A1 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP1204427A1 (en) The nasal transmucosal delivery of peptides conjugated with biocompatible polymers
WO2014081864A1 (en) Improved peptide pharmaceuticals
TNSN07039A1 (en) ASSOCIATION THERAPY USING TRANSFERRIN FUSION PROTEINS COMPRISING GLP-1
US7381707B2 (en) Treatment of dry eye
CA2302255A1 (en) Fracture healing using pthrp analogs
AU2015266854A2 (en) Improved peptide pharmaceuticals for insulin resistance
EP1792915A3 (en) Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
Gourlet et al. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors
FR2860236A1 (en) PEPTIDES HAVING PARTICULARLY ANTI-ANGIOGENIC ACTIVITY AND THERAPEUTIC APPLICATIONS THEREOF
WO2015184125A1 (en) Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
Arsenijevic et al. Vasopressin-binding sites in the pig pituitary gland: competition by novel vasopressin antagonists suggests the existence of an unusual receptor subtype in the anterior lobe
YU48997A (en) Novel biologically active proteins, their pharmaceutical compositions and procedure for obtaining thereof
US20100227815A1 (en) Site-specific pegylated linear salmon calcitonin analogues
RU2820132C2 (en) Method for improving lower urinary tract symptoms
HK40043121B (en) Synthetic peptides, prodrugs, pharmaceutical compositions and uses
CA3139959A1 (en) Method of improving lower urinary tract symptoms
TH71270B (en) Methastin derivatives and their use